SCHEDULE: State Street Discloses 5.2% Stake in Protagonist

State Street Corporation has reported a 5.2% beneficial ownership stake in Protagonist Therapeutics Inc. common stock.

Summary

• State Street Corporation has filed a Schedule 13G, indicating beneficial ownership of common stock in Protagonist Therapeutics Inc.
• The filing reports that State Street Corporation beneficially owns 3,207,774 shares of Protagonist Therapeutics Inc. common stock.
• This ownership represents 5.2% of the total outstanding shares of the class.
• State Street Corporation holds shared voting power over 3,033,685 shares and shared dispositive power over 3,207,774 shares.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The event requiring this filing occurred on June 30, 2025.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment about the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing reflects an institutional investment by a major financial services company, State Street Corporation, in a biotechnology firm, Protagonist Therapeutics Inc. Such disclosures are common for large asset managers who hold significant stakes across various industries as part of their investment portfolios.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.

Key Dates

Keywords

Protagonist Therapeutics, State Street Corporation, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology